What amount sold does CARDAX, INC. report in Form D filings?

The latest linked filings report $3.4M sold across 4 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was CARDAX, INC.'s most recent SEC filing?

CARDAX, INC.'s most recent Form D filing was on 2021-09-30.

How many investors does CARDAX, INC. have?

The most recent Form D filing lists 5 investor(s).

What type of securities does CARDAX, INC. offer?

CARDAX, INC.'s SEC Form D filings indicate debt offerings.

CARDAX, INC.

CIK: 0001544238·Pharmaceuticals·HONOLULU, HI·Corporation

Reported Sold

$3,364,222

Total Filings

Identified Offerings

Last Filed

Sep 30, 2021

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Pharmaceuticals industry

SEC EDGAR

Offering filing timeline

Sep 30, 2021Form D — New notice

Reported sold: $200,000 · Target: $500,000

Rule 506(b)·5 investors

May 19, 2017Form D/A — Amendment

Reported sold: $1,540,000 · Target: Indefinite

Rule 506(b)·50 investors

Changed: Reported amount sold, Reported investors

May 20, 2016Form D — New notice

Reported sold: $503,000 · Target: Indefinite

Rule 506(b)·10 investors

Nov 13, 2015Form D/A — Amendment

Reported sold: $1,591,222 · Target: $4,000,000

Rule 506(b)·29 investors

Changed: Reported amount sold, Offering target, Reported investors, Sales commissions

Jun 30, 2015Form D/A — Amendment

Reported sold: $1,125,000 · Target: $3,500,000

Rule 506(b)·21 investors

Changed: Reported amount sold, Reported investors

Mar 12, 2015Form D — New notice

Reported sold: $290,000 · Target: $3,500,000

Rule 506(b)·4 investors

Jun 1, 2012Form D/A — Amendment

Reported sold: $33,000 · Target: $100,000

Rule 506·33 investors

May 30, 2012Form D — New notice

Reported sold: $33,000 · Target: $100,000

Rule 506·33 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

$1 - $1,000,000

Reported commissions across identified offerings

$28,575

Amendment Rate

50%

Latest reported sold across 4 identified offerings

$3,364,222

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

David G. Watumull

Related Person

Appears on 6 filings

John B. Russell

Related Person

Appears on 5 filings

Terence A. Kelly

Related Person

Appears on 5 filings

George W. Bickerstaff III

Related Person

Appears on 5 filings

Nicholas Mitsakos

Related Person

Appears on 4 filings

David M. Watumull

Related Person

Appears on 1 filing

Tamar D. Howson

Related Person

Appears on 1 filing

Frank C. Herringer

Related Person

Appears on 1 filing

Filing History

Date	Type	Offering target	Reported sold	Investors
Sep 30, 2021	New	$500,000	$200,000	5
May 19, 2017	Amendment	Indefinite	$1,540,000	50
May 20, 2016	New	Indefinite	$503,000	10
Nov 13, 2015	Amendment	$4,000,000	$1,591,222	29
Jun 30, 2015	Amendment	$3,500,000	$1,125,000	21
Mar 12, 2015	New	$3,500,000	$290,000	4
Jun 1, 2012	Amendment	$100,000	$33,000	33
May 30, 2012	New	$100,000	$33,000	33

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

EpiVario Inc.

Pharmaceuticals

Offering target: $500,000

Filed Oct 13, 2026